ID   KGN
AC   CVCL_0375
DR   BTO; BTO:0005671
DR   CLO; CLO_0051454
DR   MCCL; MCC:0000270
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03472163
DR   cancercelllines; CVCL_0375
DR   Cell_Model_Passport; SIDM00302
DR   ChEMBL-Cells; CHEMBL3308155
DR   ChEMBL-Targets; CHEMBL2366154
DR   Cosmic; 924186
DR   Cosmic; 1149409
DR   Cosmic; 1213591
DR   Cosmic; 1305320
DR   Cosmic; 1312287
DR   Cosmic; 1429993
DR   Cosmic; 2368538
DR   Cosmic; 2697832
DR   Cosmic-CLP; 924186
DR   DepMap; ACH-002149
DR   EGA; EGAS00001000978
DR   GDSC; 924186
DR   GEO; GSM1669985
DR   IARC_TP53; 27560
DR   LINCS_LDP; LCL-1297
DR   PharmacoDB; KGN_746_2019
DR   PRIDE; PXD030304
DR   PubChem_Cell_line; CVCL_0375
DR   RCB; RCB1154
DR   Ubigene; YC-C051
DR   Wikidata; Q54899838
RX   PubMed=11145608;
RX   PubMed=15541573;
RX   PubMed=18980698;
RX   PubMed=19956657;
RX   PubMed=20098707;
RX   PubMed=20164919;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Doubling time: 46.4 hours (PubMed=11145608).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 1092; FOXL2; Simple; p.Cys134Trp (c.402C>G); ClinVar=VCV000376348; Zygosity=Heterozygous (PubMed=19956657; PubMed=20098707).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0%; Native American=0.09%; East Asian, North=73.92%; East Asian, South=24.17%; South Asian=1.82%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Derived from site: In situ; Ovary, ovarian follicle, granulosa cell layer; UBERON=UBERON_0005170.
ST   Source(s): Cosmic-CLP; RCB
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 9
ST   D16S539: 10,12
ST   D5S818: 13
ST   D7S820: 11
ST   TH01: 9
ST   TPOX: 8,9
ST   vWA: 17
DI   NCIt; C6261; Ovarian granulosa cell tumor
DI   ORDO; Orphanet_99915; Maligant granulosa cell tumor of the ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   63Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 35
//
RX   PubMed=11145608; DOI=10.1210/endo.142.1.7862;
RA   Nishi Y., Yanase T., Mu Y.-M., Oba K., Ichino I., Saito M., Nomura M.,
RA   Mukasa C., Okabe T., Goto K., Takayanagi R., Kashimura Y., Haji M.,
RA   Nawata H.;
RT   "Establishment and characterization of a steroidogenic human
RT   granulosa-like tumor cell line, KGN, that expresses functional
RT   follicle-stimulating hormone receptor.";
RL   Endocrinology 142:437-445(2001).
//
RX   PubMed=15541573; DOI=10.1016/j.mce.2004.04.018;
RA   Havelock J.C., Rainey W.E., Carr B.R.;
RT   "Ovarian granulosa cell lines.";
RL   Mol. Cell. Endocrinol. 228:67-78(2004).
//
RX   PubMed=18980698; DOI=10.1186/1471-2407-8-319;
RA   Imai M., Muraki M., Takamatsu K., Saito H., Seiki M., Takahashi Y.;
RT   "Spontaneous transformation of human granulosa cell tumours into an
RT   aggressive phenotype: a metastasis model cell line.";
RL   BMC Cancer 8:319.1-319.10(2008).
//
RX   PubMed=19956657; DOI=10.1371/journal.pone.0007988;
RA   Schrader K.A., Gorbatcheva B., Senz J., Heravi-Moussavi A., Melnyk N.,
RA   Salamanca C.M., Maines-Bandiera S.L., Cooke S.L., Leung P.C.K.,
RA   Brenton J.D., Gilks C.B., Monahan J., Huntsman D.G.;
RT   "The specificity of the FOXL2 c.402C>G somatic mutation: a survey of
RT   solid tumors.";
RL   PLoS ONE 4:E7988-E7988(2009).
//
RX   PubMed=20098707; DOI=10.1371/journal.pone.0008789;
RA   Benayoun B.A., Caburet S., Dipietromaria A., Georges A., D'Haene B.,
RA   Pandaranayaka P.J.E., L'Hote D., Todeschini A.-L., Krishnaswamy S.,
RA   Fellous M., De Baere E., Veitia R.A.;
RT   "Functional exploration of the adult ovarian granulosa cell
RT   tumor-associated somatic FOXL2 mutation p.Cys134Trp (c.402C>G).";
RL   PLoS ONE 5:E8789-E8789(2010).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//